GITNUXREPORT 2025

Acute Myeloid Leukemia Statistics

AML affects thousands annually; genetics, age influence prognosis, treatment outcomes.

Jannik Linder

Co-Founder of Gitnux, specialized in content and tech since 2016.

First published: April 29, 2025

Our Commitment to Accuracy

Rigorous fact-checking • Reputable sources • Regular updatesLearn more

Statistic 1

AML symptoms often include fatigue, fever, easy bruising, and bleeding due to bone marrow failure

Statistic 2

Anemia is present in nearly all AML patients at diagnosis

Statistic 3

Thrombocytopenia occurs in about 90% of AML patients at diagnosis, leading to increased bleeding risk

Statistic 4

Leukostasis, a dangerous complication of AML, results from high blast counts blocking blood flow, and occurs in about 3-5% of cases

Statistic 5

Leukocyte alkaline phosphatase levels are typically low in AML compared to other leukemias

Statistic 6

Approximately 20,000 new AML cases are diagnosed annually in the United States

Statistic 7

The median age at diagnosis for AML is around 68 years

Statistic 8

AML accounts for about 1.1% of all new cancer cases in the US

Statistic 9

AML results in approximately 11,540 deaths annually in the United States

Statistic 10

The incidence rate of AML is about 4.3 per 100,000 men and women per year in the US

Statistic 11

The incidence of AML has been increasing slightly over the past decades

Statistic 12

AML is more common in adults over 60 years old

Statistic 13

Approximately 80% of AML cases are diagnosed in people over age 55

Statistic 14

Common risk factors for AML include prior chemotherapy, radiation, exposure to chemicals like benzene, and genetic disorders

Statistic 15

The prevalence of AML is slightly higher in men than women

Statistic 16

The overall burden of AML is higher in developed countries due to better diagnostic capabilities and reporting

Statistic 17

Approximately 15-20% of AML cases occur in pediatric populations, making it less common than in adults

Statistic 18

The incidence of therapy-related AML (t-AML) is rising due to increased use of chemotherapy and radiation therapy

Statistic 19

AML can sometimes present as a myelodysplastic syndrome (MDS) progression, especially in older adults

Statistic 20

The prevalence of AML varies worldwide, with higher rates reported in North America and Europe compared to Asia and Africa

Statistic 21

There are several subtypes of AML classified by the WHO based on genetic, morphologic, immunophenotypic, and clinical features

Statistic 22

About 50-70% of AML patients have detectable chromosomal abnormalities

Statistic 23

The most common genetic mutation in AML involves FLT3, found in approximately 30% of cases

Statistic 24

Mutations in the NPM1 gene are present in around 30% of AML cases, especially in patients without FLT3 mutations

Statistic 25

AML is classified into various risk groups based on cytogenetics, with genetic abnormalities influencing prognosis

Statistic 26

The presence of certain cytogenetic abnormalities like inv(16) and t(15;17) can indicate favorable prognosis

Statistic 27

The World Health Organization updated AML classification in 2016 to include molecular genetic data

Statistic 28

AML is a heterogeneous disease with varying responses to treatment based on molecular and cytogenetic profiles

Statistic 29

The 5-year relative survival rate for AML is approximately 30%

Statistic 30

The relapse rate in AML patients who achieve remission can be as high as 50-70%

Statistic 31

Conversely, mutations like complex karyotypes are associated with poor outcomes in AML

Statistic 32

Treatment-related AML generally has a worse prognosis than de novo AML

Statistic 33

Minimal residual disease (MRD) testing is increasingly used to predict relapse risk post-treatment

Statistic 34

Elderly AML patients often have poorer outcomes due to comorbidities and less aggressive treatment options

Statistic 35

The average duration of initial remission in AML varies but can be around 12-18 months with current treatments

Statistic 36

The prognosis of AML is heavily influenced by genetic and molecular markers, making testing essential for treatment planning

Statistic 37

Studies show that early detection and initiation of therapy improve the survival rates in AML patients

Statistic 38

The median survival for patients with poor-risk cytogenetics is often less than 1 year, highlighting the need for novel therapies

Statistic 39

Relapse-free survival is significantly improved in patients receiving stem cell transplantation in first remission compared to chemotherapy alone

Statistic 40

Targeted therapies such as FLT3 inhibitors have been developed for specific AML mutations

Statistic 41

Standard induction chemotherapy for AML typically involves cytarabine and an anthracycline

Statistic 42

The complete remission rate after initial chemotherapy in AML patients ranges between 60-80%

Statistic 43

Allogeneic stem cell transplant can be a potentially curative option for selected AML patients

Statistic 44

The median time from diagnosis to treatment initiation is typically 2-3 days

Statistic 45

Recent advances include the approval of targeted agents like midostaurin for FLT3-mutated AML

Statistic 46

New therapies like venetoclax combined with hypomethylating agents are showing promise in elderly AML populations

Statistic 47

The cost of AML treatment can exceed $300,000 per patient in the US, considering hospitalization, drugs, and stem cell transplants

Statistic 48

Recent clinical trials focus on immunotherapy approaches such as leukocyte targeting and immune checkpoint inhibitors

Statistic 49

Gemtuzumab ozogamicin, an antibody-drug conjugate targeting CD33, was reapproved by the FDA for AML treatment in 2017

Statistic 50

The use of next-generation sequencing has improved diagnostic accuracy and personalized treatment planning in AML

Statistic 51

AML in adults rarely responds to traditional chemotherapy alone in elderly patients, increasing interest in targeted and immunotherapies

Statistic 52

Several clinical trials are investigating the efficacy of CAR T-cell therapy in AML treatment, although challenges remain

Slide 1 of 52

Sources

Our Reports have been cited by:

Trust Badges - Publications that have cited our reports

Key Highlights

Approximately 20,000 new AML cases are diagnosed annually in the United States
The median age at diagnosis for AML is around 68 years
AML accounts for about 1.1% of all new cancer cases in the US
The 5-year relative survival rate for AML is approximately 30%
AML results in approximately 11,540 deaths annually in the United States
The incidence rate of AML is about 4.3 per 100,000 men and women per year in the US
The incidence of AML has been increasing slightly over the past decades
AML is more common in adults over 60 years old
Approximately 80% of AML cases are diagnosed in people over age 55
There are several subtypes of AML classified by the WHO based on genetic, morphologic, immunophenotypic, and clinical features
Common risk factors for AML include prior chemotherapy, radiation, exposure to chemicals like benzene, and genetic disorders
About 50-70% of AML patients have detectable chromosomal abnormalities
The most common genetic mutation in AML involves FLT3, found in approximately 30% of cases

With approximately 20,000 new cases diagnosed annually in the United States and a five-year survival rate of just 30%, Acute Myeloid Leukemia remains a formidable challenge in cancer care, particularly among older adults.

Clinical Characteristics and Subtypes

AML symptoms often include fatigue, fever, easy bruising, and bleeding due to bone marrow failure
Anemia is present in nearly all AML patients at diagnosis
Thrombocytopenia occurs in about 90% of AML patients at diagnosis, leading to increased bleeding risk
Leukostasis, a dangerous complication of AML, results from high blast counts blocking blood flow, and occurs in about 3-5% of cases
Leukocyte alkaline phosphatase levels are typically low in AML compared to other leukemias

Clinical Characteristics and Subtypes Interpretation

While AML’s symptoms like fatigue, bruising, and bleeding cloak it in clinical plainclothes, its hallmark low alkaline phosphatase levels and frequent anemia serve as signs—sometimes subtle, sometimes startling—that the bone marrow's mischief demands urgent expert intervention.

Epidemiology and Demographics

Approximately 20,000 new AML cases are diagnosed annually in the United States
The median age at diagnosis for AML is around 68 years
AML accounts for about 1.1% of all new cancer cases in the US
AML results in approximately 11,540 deaths annually in the United States
The incidence rate of AML is about 4.3 per 100,000 men and women per year in the US
The incidence of AML has been increasing slightly over the past decades
AML is more common in adults over 60 years old
Approximately 80% of AML cases are diagnosed in people over age 55
Common risk factors for AML include prior chemotherapy, radiation, exposure to chemicals like benzene, and genetic disorders
The prevalence of AML is slightly higher in men than women
The overall burden of AML is higher in developed countries due to better diagnostic capabilities and reporting
Approximately 15-20% of AML cases occur in pediatric populations, making it less common than in adults
The incidence of therapy-related AML (t-AML) is rising due to increased use of chemotherapy and radiation therapy
AML can sometimes present as a myelodysplastic syndrome (MDS) progression, especially in older adults
The prevalence of AML varies worldwide, with higher rates reported in North America and Europe compared to Asia and Africa

Epidemiology and Demographics Interpretation

While AML remains a relatively small slice of the cancer pie, its increasing incidence and deadly toll—especially among seniors—serve as a stark reminder that when it comes to blood cancers, early detection and prevention are just as critical as the latest treatments.

Genetic and Molecular Factors

There are several subtypes of AML classified by the WHO based on genetic, morphologic, immunophenotypic, and clinical features
About 50-70% of AML patients have detectable chromosomal abnormalities
The most common genetic mutation in AML involves FLT3, found in approximately 30% of cases
Mutations in the NPM1 gene are present in around 30% of AML cases, especially in patients without FLT3 mutations
AML is classified into various risk groups based on cytogenetics, with genetic abnormalities influencing prognosis
The presence of certain cytogenetic abnormalities like inv(16) and t(15;17) can indicate favorable prognosis
The World Health Organization updated AML classification in 2016 to include molecular genetic data
AML is a heterogeneous disease with varying responses to treatment based on molecular and cytogenetic profiles

Genetic and Molecular Factors Interpretation

Despite advances in genetic profiling transforming AML from an inscrutable foe into a disease with nuanced subtypes and prognostic clues, its heterogeneity underscores a sobering reality: personalized medicine remains essential, as a one-size-fits-all approach is increasingly outdated in battling this genetically complex leukemia.

Prognosis and Outcomes

The 5-year relative survival rate for AML is approximately 30%
The relapse rate in AML patients who achieve remission can be as high as 50-70%
Conversely, mutations like complex karyotypes are associated with poor outcomes in AML
Treatment-related AML generally has a worse prognosis than de novo AML
Minimal residual disease (MRD) testing is increasingly used to predict relapse risk post-treatment
Elderly AML patients often have poorer outcomes due to comorbidities and less aggressive treatment options
The average duration of initial remission in AML varies but can be around 12-18 months with current treatments
The prognosis of AML is heavily influenced by genetic and molecular markers, making testing essential for treatment planning
Studies show that early detection and initiation of therapy improve the survival rates in AML patients
The median survival for patients with poor-risk cytogenetics is often less than 1 year, highlighting the need for novel therapies
Relapse-free survival is significantly improved in patients receiving stem cell transplantation in first remission compared to chemotherapy alone

Prognosis and Outcomes Interpretation

Despite advancements in detection and treatment, acute myeloid leukemia remains a formidable foe—with only about a third of patients surviving five years, relapse rates soaring up to 70%, and genetics and age continuing to dictate the battle’s brutal outcomes, underscoring the urgent need for more personalized and innovative therapies.

Treatment and Therapeutic Advances

Targeted therapies such as FLT3 inhibitors have been developed for specific AML mutations
Standard induction chemotherapy for AML typically involves cytarabine and an anthracycline
The complete remission rate after initial chemotherapy in AML patients ranges between 60-80%
Allogeneic stem cell transplant can be a potentially curative option for selected AML patients
The median time from diagnosis to treatment initiation is typically 2-3 days
Recent advances include the approval of targeted agents like midostaurin for FLT3-mutated AML
New therapies like venetoclax combined with hypomethylating agents are showing promise in elderly AML populations
The cost of AML treatment can exceed $300,000 per patient in the US, considering hospitalization, drugs, and stem cell transplants
Recent clinical trials focus on immunotherapy approaches such as leukocyte targeting and immune checkpoint inhibitors
Gemtuzumab ozogamicin, an antibody-drug conjugate targeting CD33, was reapproved by the FDA for AML treatment in 2017
The use of next-generation sequencing has improved diagnostic accuracy and personalized treatment planning in AML
AML in adults rarely responds to traditional chemotherapy alone in elderly patients, increasing interest in targeted and immunotherapies
Several clinical trials are investigating the efficacy of CAR T-cell therapy in AML treatment, although challenges remain

Treatment and Therapeutic Advances Interpretation

Despite a promising array of targeted therapies, immunotherapies, and personalized diagnostics transforming AML treatment from a 60-80% remission gamble to a high-stakes medical frontier, the steep costs, rapid diagnosis-to-treatment window, and persistent resistance underscore that we're still racing to turn innovative science into universally effective cures.